RxDoctor Payments Data

John Salazar

Family · Mesa, AZNPI 1760863955

Payments from drug & device makers

$6,599in general payments, 2019–2025

Across 175 payments — averaging $37.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Nevro Corp.$1K
  • Abbott$689
  • Vertos Medical, Inc.$451
  • Collegium Pharmaceutical, Inc.$377
  • Nalu Medical, Inc.$288
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$1252%
  • Travel & lodging$77812%
  • Food & beverage$5,68486%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,599 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$28,701
Medicare patients
91
Services billed
1,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl45$38,963
MovantikNaloxegol Oxalate66$30,191
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen349$13,070
Etodolac187$7,795
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen234$7,049
Celecoxib71$5,559
Buprenorphine22$4,905
Baclofen228$3,640
Gabapentin246$3,440
Oxycodone Hcl216$3,086
Pregabalin115$2,973
Tizanidine Hcl150$2,293
Diclofenac Sodium51$1,962
Tramadol Hcl117$1,841
Cyclobenzaprine Hcl109$1,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$377$38,96345 claims
Redhill Biopharma Inc.Movantik$150$30,19166 claims
Virtus Pharmaceuticals LLCLactulose$17$22528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →